Palbociclib

LCZ696 是美国 Novartis Pharmaceuticals 开发的一种心力衰竭治疗药物。心力衰竭是一种危及生命、使人衰弱的疾病，其中心脏无法泵出足够的血液来供应身体。呼吸急促、疲劳和体液潴留等症状可能会逐渐发展并随着时间的推移而恶化，从而严重影响生活质量。

The LCZ696 intermediate is an important organic synthesis and pharmaceutical research intermediate, primarily used for the synthesis of LCZ696 (Entresto). LCZ696 is a dual-acting angiotensin receptor neprilysin inhibitor (ARNI) composed of sacubitril and valsartan, and is widely used in the treatment of ca...

Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). Val-cit-PAB-OH is a degradable ADC linker.

Monomethyl auristatin E, abbreviated as MMAE, is a synthetic antitumor agent. Due to its toxicity, it cannot be used as a drug alone but is instead conjugated to monoclonal antibodies (mAb). It is an effective antimitotic agent derived from dolastatin, a peptide found in the marine mollusk Dolabella auricu...

Payload Classifications:Auristatin derivativesWe can provide high-quality MMAE and its derived impurities.

VcMMAE (mc-vc-PAB-MMAE) is a biochemical reagent and a component of antibody-drug conjugates (ADCs) as a drug-linker conjugate. It exhibits anticancer activity and is composed of MMAE (a tubulin inhibitor) connected via a Vc linker, as described on Chemicalbook.

Palbociclib (monohydrochloride) is a highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which play a crucial role in regulating cell cycle progression. By inhibiting CDK4/6, Palbociclib effectively arrests cell cycle progression, particularly in cancer cells that rely on CDK4/6 activi...

特格拉赞  AP≥99.O%

AP>99%

4-(6-Aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester is a pharmaceutical intermediate, primarily used for the synthesis of the active pharmaceutical ingredient Palbociclib.

Trabectedin （Yondelis） 是一种烷化剂，用于治疗既往接受过含蒽环类药物方案的不可切除或转移性脂肪肉瘤或平滑肌肉瘤患者。

VcMMAE (mc-vc-PAB-MMAE) is a biochemical reagent and a part of antibody-drug conjugates (ADCs) as a drug-linker conjugate. It exhibits anticancer activity and is composed of MMAE (a tubulin inhibitor) connected via a Vc linker.

ChemExpress have been shortlisted for Best CRO (Contract Research Organization) at the 11th World ADC Awards. 

Founded in 2006, ChemExpress focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. Our comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. We are a one-stop service platform to support our client’s projects from early drug discovery, process development to commercialization.

ChemExpress have received EIR with the conclusion of the inspection, no FDA 483, Observations, was issued by US FDA on August 8th.

ChemExpress CDMO Services brochure (CDMO）

ChemExpress focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. 

ChemExpress ADC Products handbook (ADC)

ChemExpress FTE & FFS Services Flyer (FTE&FFS)

DMF Filed ADC Small Molecule Products